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Abstract
In the last decade, Acute Kidney Injury (AKI) diagnosis and therapy have not notably im-
proved probably due to delay in the diagnosis, among other issues. Precocity and accuracy
should be critical parameters in novel AKI biomarker discovery. microRNAs are key regula-
tors of cell responses to many stimuli and they can be secreted to the extracellular environ-
ment. Therefore, they can be detected in body fluids and are emerging as novel disease
biomarkers. We aimed to identify and validate serum miRNAs useful for AKI diagnosis and
management. Using qRT-PCR arrays in serum samples, we determined miRNAs differen-
tially expressed between AKI patients and healthy controls. Statistical and target prediction
analysis allowed us to identify a panel of 10 serum miRNAs. This set was further validated,
by qRT-PCR, in two independent cohorts of patients with relevant morbi-mortality related to
AKI: Intensive Care Units (ICU) and Cardiac Surgery (CS). Statistical correlations with pa-
tient clinical parameter were performed. Our results demonstrated that the 10 selected miR-
NAs (miR-101-3p, miR-127-3p, miR-210-3p, miR-126-3p, miR-26b-5p, miR-29a-3p, miR-
146a-5p, miR-27a-3p, miR-93-3p and miR-10a-5p) were diagnostic biomarkers of AKI in
ICU patients, exhibiting areas under the curve close to 1 in ROC analysis. Outstandingly,
serum miRNAs estimated before CS predicted AKI development later on, thus becoming
biomarkers to predict AKI predisposition. Moreover, after surgery, the expression of the
miRNAs was modulated days before serum creatinine increased, demonstrating early diag-
nostic value. In summary, we have identified a set of serummiRNAs as AKI biomarkers use-
ful in clinical practice, since they demonstrate early detection and high diagnostic value and
they recognize patients at risk.
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Introduction
Acute Kidney Injury (AKI) is a frequent clinical syndrome with incidence of 550 cases per
100,000 individuals, similar to the myocardial infarction rate per year [1, 2]. In hospitalized pa-
tients, AKI incidence can reach 13%, depending on the diagnostic criteria employed [3]. In the
setting of cardiac surgery, AKI incidence reaches approximately 35% and kidney injury severity
is critical for patient outcome after the intervention [4]. AKI still presents a very high morbidity
and mortality, especially in intensive care units (ICU), where mortality can reach 50–70%. AKI
survivors exhibit a significant risk of developing chronic morbidities, such as chronic kidney
disease (CKD), or accelerated end-stage renal disease development.
Despite great advances in prevention strategies, patient classification and technology, no ef-
ficient therapy is available once AKI occurs, most probably due to delay in the diagnosis. Even
though its widespread use, serum creatinine shows important and well-known limitations for
assessing Glomerular Rate Filtration (GFR) [5], including the delay in the diagnosis or their
values modification by drugs. Novel biomarkers such as NGAL or Cistatin did not exhibit the
diagnostic value expected in all the AKI populations. All these caveats impact on the current
AKI definitions used in clinical practice and point out the urgent need for new AKI biomarkers
identification in order to improve AKI diagnosis and patient management. In fact, novel bio-
markers for structural AKI are emerging since they could lead to a better stratification of pa-
tients and provide additional information to the functional ones [6], including miRNAs
miRNAs are small (20–25 nucleotides) endogenous RNAmolecules which post-transcrip-
tionally regulate gene expression [7]. miRNAs play critical roles in kidney development,
homeostasis and function, including kidney physiology [8]. Additionally, they are also key
mediators in renal responses to injury, such as ischemia/reperfusion damage [9, 10]. It has
been widely demonstrated that miRNAs can also be secreted to the extracellular environment,
with potential functional consequences [11, 12]. This secretion allows them to be detected in a
wide range of cell-free body fluids including urine or serum. Indeed, changes in serum miRNA
profiles have been proposed as biomarkers for a wide range of diseases such as cancer, cardio-
vascular disease, and nephropathies, among others [13]. Thus, it is conceivable that serum
miRNAs could be a useful tool for AKI diagnosis. In fact, recent reports have identified miR-
NAs associated with AKI in urine from ICU patients [14] as well as in plasma and in serum of
animal experimental models of AKI [15], including toxic AKI [16].
In this pilot study, we have aimed to identify and validate a panel of serum miRNAs that
could be useful for AKI diagnosis in clinical practice. We have used serum samples from ICU
patients and cardiac surgery (CS) patients, two clinical situations where AKI incidence is high.
We also aimed to study whether this set of miRNAs could also provide further clinical insight,
thus allowing better monitoring and management of AKI patients.
Material and Methods
1. Human serum sample collection and storage
All our patient studies were approved by the Institutional Review Boards. Written informed
consent document was received from participants prior to inclusion in the study. Samples and
data from patients as well as healthy volunteers were provided by the University Hospital
Ramóxn y Cajal-IRYCIS Biobank, integrated in the Spanish Hospital Biobanks Network
(RetBioH; www.redbiobancos.es), with appropriate approval of the Ethical and Scientific Com-
mittees and according to the quality standard guidelines (ISO 9001:2008). Serum was obtained
by centrifugation at 1,100 g for 10 minutes at 4°C, then aliquoted and immediately stored at
-80°C. Stability of miRNAs after freeze/thaw cycles was demonstrated.
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2. Patient Cohorts
Our study is a Pilot observational prospective study with different patient cohorts used for pro-
filing or validation studies:
2.1. Cohorts for miRNA profiling experiments. 2.1.1. Samples from healthy volunteers
with normal renal function and no major pathologies were divided into two pools (n = 5 indi-
vidual each) taking into account age and sex distribution, in order to minimize interpersonal
variations and increase the robustness of difference between healthy individuals and patients.
2.1.2. AKI patients: samples of this cohort were selected from Biobank collection (Reference:
AD4-FRA). This collection is composed of patients exhibiting AKI subsequent to acute tubular
necrosis, exclusively, excluding other pathologies and multiorganic failure.
2.2 Cohorts for miRNA validation in Intensive Care Units (ICU) patients. 2.2.1. Sam-
ples are from 20 healthy individuals in the Biobank collection (Reference AD5- BCS). These
samples are coming from Hospital blood donors and they are used as healthy controls.
2.2.2. Samples from 35 ICU patients diagnosed with AKI in the context of multiorganic failure
were obtained from Biobank collection (Reference AD1-FMO). AKI was diagnosed using serum
creatinine AKIN criteria [17]. Patients were diagnosed with pre-renal azotemia when serum cre-
atinine returned to baseline after adequate treatment in less than 72 hours. For each patient, we
analyzed serum samples collected at day 0 (Diagnosis), day 1, day 2, day 3 and day 7.
2.3. Cohorts for miRNA validation in Cardiac Surgery (CS) Patients. 41 CS patients
were collected and stored in Ramon y Cajal Hospital Biobank (collection reference AD3-CEC).
To be included in this cohort, patients conform to the following criteria:
• I: paediatric naïve patients operated with cardiopulmonary bypass (10 individuals).
• II: adult patients with 0–2 points in Thakar score system for AKI prediction after surgery
[18]. (10 individuals).
• III: adult patients with altered baseline renal function and> 5 points in Thakar score (14
individuals).
• IV: adult patients with normal renal function and> 5 points in Thakar system (7 individuals).
AKI was diagnosed using AKIN [17] and RIFLE [19] serum creatinine criteria and creatinine
kinetics [20] definitions independently. For each patient, serum samples were collected: before
surgery (Baseline), immediately post-surgery (IPS), and at 1, 2,3 and 7 days after surgery.
3. RNA extraction from serum samples
Total RNA was extracted with miRNeasy mini kit (Qiagen) using an optimized protocol. Brief-
ly, 250 μl aliquots were thawed on ice and centrifuged 1,000g for 5 minutes at 4°C to remove
debris. For each sample, 800 μl of phenol master mix was prepared, containing 1 μg of MS2
RNA (Roche). For data normalization during miRNA detection by quantitative real time PCR
(RT-qPCR), 2x106 copies of Spike-In synthetic RNA oligo (Unknown sequence; Exiqon) were
added to this master mix. 750 μl of master mix were used for each 200 μl of precleared serum
sample. The following steps were carried out according to manufacturer´s instructions. RNA
was eluted by adding 50 μl of nuclease free water.
4. microRNA RT-qPCR Array and data analysis
Circulating miRNA profiling experiments were carried out using Taqman Low Density Arrays
for miRNAs (Applied Biosystems). For each sample, total RNA from three different aliquots
was extracted as detailed above to avoid aliquot or RNA extraction procedure variability. After
SerummicroRNAs as Acute Kidney Injury Biomarkers
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RNA quantification and quality checking, RNA samples were pooled for further steps. Reverse-
transcription was performed using Megaplex RT primer pool panel A and B and Taqman
miRNA retrotranscription kit (Applied Biosystems) following manufacturer´s instructions.
PCR determinations were performed using Taqman Array Human microRNA cards (Ap-
plied Biosystems) following manufacturer’s instructions. All reactions were carried out in a
7900HT Fast Real-Time PCR System and raw Cq were obtained using SDS v2.3 software (Ap-
plied Biosystems).
Raw Cq values were exported and analyzed in Excel (Microsoft). First, miRNAs not express-
ed in any sample were eliminated. After this step, all values showed as “undetermined” were
substituted by 40 as Cq value. Next, ΔCq values were calculated (ΔCq = miRNA Cq—Reference
gene Cq) using as reference control the mean of the Cq values of all expressed miRNAs (Cq
values<35) [21]. Next, miRNA with inconsistent ΔCq values between control samples
(ΔΔCq>1) were also excluded from the study.
After these initial selection steps, based on technical criteria, fold changes were calculated using
2-ΔΔCq method. miRNAs showing statistically significant changes over ±2 fold were selected.
5. microRNA quantification by LNA probes
Serum miRNAs were detected and quantified by Real-Time PCR using Universal RT miRNA
PCR System (Exiqon). 4 μl of the eluted RNA was used as template for retrotranscription in a
final volume of 20 μl. cDNA was diluted 1/11 with nuclease-free sterile water and 4 μl was used
as template for PCR reaction.
Real time PCR detection was performed using SYBR Green and specific commercially avail-
able probes (Exiqon) for each miRNA of interest. Master Mix preparation and temperature cy-
cles were performed following manufacturer’s instructions. All reactions were carried out in
triplicates in Light Cycler 480 equipment (Roche) and Cq values were calculated using 2nd de-
rivative method (Light Cycler 480 Software 1.5, Roche). miRNA expression values are express-
ed as ΔCq, obtained from the following formula: ΔCq = miRNA Cq—Spike In Cq.
As previously mentioned, miRNA stability after few freeze/thawing cycles was checked in
our lab demonstrating high stability, as previously reported [22].
6. Statistical Analysis
Normal distribution of variables was assessed with the Saphiro-Wilk test. For data with normal
distribution, t-test and ANOVA with post hoc Bonferroni correction for multiple comparisons
were used after assessing homogeneity of variances with the Levene test. For group comparison
of non-normal distributed data, Kruskal—Wallis test was used. Intergroup differences of non-
normal data were assessed with post hoc Mann—Whitney U-tests. Spearman Rho correlation
coefficient was used for correlation studies.
ROC curve test was used to evaluate diagnostic performance. P<0.05 was considered signif-
icant. Statistical analyses were performed using Statistical Package for the Social Sciences
(SPSS) software version 19.0.
Results
Identification of serummiRNAs differentially expressed between healthy
volunteers and AKI patients
We performed a screening experiment using RT-qPCR arrays, including 786 miRNAs. For this
initial experiment, two pools of healthy people (n = 5 each) and 4 AKI patients were included.
Clinical settings of these patients are shown in Table 1.
SerummicroRNAs as Acute Kidney Injury Biomarkers
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After elimination of unexpressed or inconsistently expressed miRNAs, based on technical
criteria, miRNAs with more than ±2 folds change in expression and statistical significance
were selected (Table 2).
In order to contextualize the selected miRNAs in AKI, we performed a bioinformatics
functional analysis. For each miRNA, potential targets were downloaded from Targetscan
Human 5.1 database (http://www.targetscan.org/vert_50/) [23]. Target gene list were then an-
alyzed using the online Bioinformatics Database for Annotation, Visualization and Integrated
Discovery (DAVID) (http://david.abcc.ncifcrf.gov/tools.jsp), using default settings [24]. As
can be observed in S1 Table, selected miRNAs show targets genes involved in renal response
during AKI.
After selection, this panel of miRNAs was validated in a cohort of ICU patients with AKI
and a cohort of cardiac surgery patients. Both clinical contexts were chosen based on the high
incidence of AKI.
SerummiRNAs are diagnostic Biomarkers of AKI in ICU Patients
Clinical settings for ICU patients and controls used for validation can be found in Table 3. Se-
lected serum microRNAs were detected in samples obtained at the time of diagnosis (Fig 1A).
In agreement with data obtained in the screening experiment, studied miRNAs were markedly
downregulated (higher ΔCp values) in AKI samples compared to healthy controls. Fig 1B
shows raw Cp values of Spike-In RNA in these samples, used as control for miRNA quantifi-
cation. These values show no statistical significance between healthy and AKI samples
(p-value = 0.081), demonstrating its reliability as RT-qPCR reference gene control.
Receiver Operator Characteristic (ROC) curve analysis was performed to study the diagnos-
tic performance of each of these miRNAs for AKI. As can be observed in Fig 1C and Table 4,
all miRNAs presented areas under the curve (AUC) values between 0.9 and 1. Additional infor-
mation regarding ROC analysis is shown in S2 Table.
Moreover, correlation analysis demonstrated that serum levels of miR-210-3p, miR-126-3p,
miR-29a-3p and miR-146a-5p correlate with AKI severity, estimated by AKIN criteria [17]
(miR-210-3p p-value = 0.001; miR-126-3p p-value = 0.021; miR-29a-3p p-value = 0.009;
miR146a-5p p-value = 0.008) (Fig 2).
These data demonstrate that our panel of serum miRNAs could be used for AKI diagnosis
with nearly 100% sensitivity and specificity in this cohort. Additionally, serum levels of miR-
210-3p, miR-126-3p, miR-29a-3p and miR-146a-5p could indicate AKI severity in a single
determination.
Table 1. Clinical settings of AKI patients and healthy control pools included in the screening experiment.
Age Gender AKIN Stage Serum Creatinine (mg/dl)
Healthy Control
Pool 1 (n = 5) 32.8 ± 5.8* 2 Men/3 Women N/A 0.85 ± 0.12*
Pool 2 (n = 5) 36.6 ± 8.6* 3 Men/2 Women N/A 0.74 ± 0.13*
AKI Patients
1 41 Man 3 13.00
2 45 Woman 3 4.81
3 63 Woman 3 1.53
4 47 Man 2 5.01
N/A: Not Applicable
* Data expressed as mean ± standard deviation
doi:10.1371/journal.pone.0127175.t001
SerummicroRNAs as Acute Kidney Injury Biomarkers
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SerummiRNAs are early Biomarkers of AKI in CS patients
In addition to the ICU cohort, we have used CS patient samples since this experimental design
allow us to monitor and collect samples during AKI development. Clinical settings for these pa-
tients can be found in Table 5. We analyzed the expression of our panel of miRNAs in the sam-
ples collected before AKI diagnosis (days 1, 2, and 3 before AKI development). Spearman Rho
correlation coefficient was calculated to find out statistically significant correlations between
miRNA expression and time-points before AKI diagnosis, based on AKIN criteria [17]. As can
be observed in Fig 3, miR-26b-5p, miR-146a-5p, miR-93-3p and miR-127-3p showed a pro-
gressive downregulation during the days prior to AKI diagnosis.
These data, in agreement with the data obtained in ICU patients, indicate that serum miR-
NAs are diagnostic biomarkers of AKI. Moreover, miRNAs were able to predict AKI develop-
ment several days before serum creatinine, allowing monitoring and serving as early AKI
biomarkers.
Table 2. miRNAs selected from themassive screening experiment to be tested as potential AKI biomarkers.
miRNA ID Accession Number Fold Change p-value
hsa-miR-101-3p MIMAT0000099 -2.75 0.049
hsa-miR-127-3p MIMAT0000446 -2.01 0.047
hsa-miR-210-3p MIMAT0000267 -3.15 0.030
hsa-miR-126-3p MIMAT0000445 -5.75 0.036
hsa-miR-26b-5p MIMAT0000083 -7.52 0.024
hsa-miR-29a-3p MIMAT0000086 -6.62 0.031
hsa-miR-146a-5p MIMAT0000449 -8.50 0.021
hsa-miR-27a-3p MIMAT0000084 -5.09 0.001
hsa-miR-93-3p MIMAT0004509 -22.03 0.017
hsa-miR-10a-5p MIMAT0000253 -32.21 0.001
doi:10.1371/journal.pone.0127175.t002
Table 3. Clinical settings of ICU patient cohort and healthy controls.
Healthy Control (n = 20) AKI Patients (n = 35)
Age (years) 38.35 ± 11.42 64.9 ± 15.5
Male (n, %) 12, 60% 28, 80%
Female (n, %) 8, 40% 7, 20%
Serum Creatinine (mg/dl)
0.76 ± 0.16 2.73 ± 4.47








SOFA N/A 6.37 ± 3.68
N/A: Not Applicable
doi:10.1371/journal.pone.0127175.t003
SerummicroRNAs as Acute Kidney Injury Biomarkers
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Fig 1. SerummicroRNAs are diagnostic biomarkers of AKI in ICU patients. (A) miRNAs were detected by RT-qPCR in serum samples from ICU patients
and healthy controls. miRNA levels are expressed as ΔCp and data are presented as median and interquartile range. Asterisks indicate statistical
significance (*P<0.05; ** P<0.01) (B) Spike-In raw Cp values as control. (C) ROC curve analysis.
doi:10.1371/journal.pone.0127175.g001
SerummicroRNAs as Acute Kidney Injury Biomarkers
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Table 4. ROC Curve analysis of ICU patients in the moment of AKI diagnosis compared to healthy
control.
microRNA ROC Analysis Day 0 (Diagnosis)
AUC S.E.M. p-value
miR-101-3p 1.000 0.000 0.000
miR-210-3p 0.935 0.034 0.000
miR-126-3p 0.979 0.015 0.000
miR-26b-5p 1.000 0.000 0.000
miR-29a-3p 0.948 0.27 0.000
miR-146a-5p 1.000 0.000 0.000
miR-27a-3p 0.955 0.025 0.000
miR-93-3p 0.942 0.029 0.000
miR-10a-5p 1.000 0.000 0.000
miR-127-3p 0.939 0.033 0.000
S.E.M: Standard error of the mean
doi:10.1371/journal.pone.0127175.t004
Fig 2. SerummicroRNAs indicate AKI severity. SerummiRNAs were detected by qRT-PCR in samples
from ICU patients at the moment of AKI diagnosis. (A) Serum levels of miR-210-3p, miR-126-3p, miR-29a-3p
and miR-146a-5p correlate with AKI severity determined by AKIN classification and with increasing severity
from 1 to 3 stage. miRNA expression levels are shown as ΔCp values and each patient is represented by an
individual dot. Spearman correlation was performed for each miRNA and p-values are shown in the
corresponding plots. Asterisks indicate statistical significance (*P<0.05 and ** P<0.01).
doi:10.1371/journal.pone.0127175.g002
SerummicroRNAs as Acute Kidney Injury Biomarkers
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SerummiRNAs are Biomarkers of AKI Predisposition in CS
In order to identify AKI predisposition biomarkers in CS population, miRNAs included in our
panel were determined in basal serum samples of CS patients, which were obtained before the
intervention. Those miRNAs showing significant changes using all AKI definitions were con-
sidered as real biomarkers of AKI development after surgery.
miR-26b-5p, miR-27a-3p, miR-93-3p and miR-127-3p were significantly downregulated in
basal serum samples of those patients who develop AKI after surgery, compared to those who
do not develop AKI (Fig 4A), indicating that these miRNAs could be biomarkers of AKI pre-
disposition in this cohort. Spike-In raw Cp values do not significantly change between patients
who develop AKI and those who do not develop AKI after surgery in any of the used classifica-
tions (RIFLE: p-value = 0.450; AKIN: p-value = 0.725; Cr Kinetics: p-value = 1) (Fig 4B).
As it is shown in Fig 5 and Table 6, these miRNAs exhibited significant AUC values between
0.7–0.9, depending on the AKI definition criteria used. Additional information regarding ROC
analysis is shown in S3 Table.
These results strongly suggest that these four miRNAs, determined before surgery, could be
used for identification of patients at risk of AKI development.
Discussion
In this pilot study, we identified and validated a set of miRNAs, including miR-101-3p, miR-
127-3p, miR-210-3p, miR-126-3p, miR-26b-5p, miR-29a-3p, miR-146a-5p, miR-27a-3p, miR-
93-3p and miR-10a-5p, as potential biomarkers of AKI in ICU and CS patients.
Table 5. Clinical settings of cardiac surgery patient cohort.
I(n = 10) II(n = 10) III(n = 14) IV(n = 7)
Age (years) 52.3 (10.6–108.4)* 65.6 ± 10.4 74.8 ± 6.9 62.0 ± 12.3
Gender (Men/Women) 7/3 5/5 4/10 5/2
BMI (kg/m2) 14.5 ± 2.3 27.5 ±3.6 26.7 ± 3.7 28.1 ± 2.7
CPB Time (min) 58.1 ± 20.3 96.6 ± 31.7 101.7 ± 34.7 105.2 ± 33.6
ICU Stay (days) 3 (3–5); 6.9 ± 11.6 3 (2–6);3.6 ± 2.1 6.5 (2–10); 10.3 ± 16.5 7 (2–12.5); 7.3 ± 5.1
Basal Serum Cr. (mg/dl) 0.57 ± 0.1 0.9 ± 0.1 1.2 ± 0.3 0.95 ± 0.3
24h Serum Cr. (mg/dl) 0.55 ± 0.1 0.8 ± 0.2 1.1 ± 0.4 1.02 ± 0.6
Discharge Serum Cr (mg/dl) 0.5 ± 0.1 0.8 ± 0.2 1.19 ± 0.4 1.19 ± 0.6
Mortality Prediction
LogEuroSCORE N/A 4.08 ± 3.05 9.7 ± 4.4 9.8 ± 7.8
Cleveland Score N/A 1.8 ± 0.9 3.83 ± 1.0 4.25 ± 1.0
SRI Score N/A 1 ± 0.5 3.45 ± 0.5 3.0 ± 0.5
AKI Development
RIFLE Cr (n) 1 1 4 4
RIFLE Diuresis (n) 0 4 3 1
Estimated GFR (n) 0 3 4 4
AKIN Cr. (n) 1 4 9 4
Cr. Kinetics (n) 1 1 7 1
BMI: Body Mass Index
N/A: Not Applicable
LOS: Length of Stay.
Cr: Creatinine.
* Age for children (median, 25th— 75th percentiles) is expressed in months
doi:10.1371/journal.pone.0127175.t005
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Genome wide profiling experiments have demonstrated that some of these miRNAs (miR-
10a, miR-27a, miR-29a, miR-101 and miR-210) are highly expressed in human kidney tissue
[25, 26]. Indeed, it has been confirmed the presence of some of these miRNAs in serum micro-
vesicles [27].
Some of these miRNAs have also been related to kidney injury. miR-127 has been recently
demonstrated as a regulator of proximal tubule cell adhesion and trafficking during Ischemia/Re-
perfusion (I/R) injury [9]. miR-146a is modulated in an experimental model of renal I/R in mice
[28] and in patients with IgA nephropathy, where its levels in renal tissue and urine were corre-
lated with injury severity [29]. miR-29a is associated with kidney fibrosis regulation and CKD
progression. This miRNA is regulated by Transforming growth Factor β (TGF-β) and its expres-
sion prevents fibrosis by avoiding extracellular matrix deposition in renal parenchyma [30].
Remarkably, Lorenzen JM. et al., reported that miR-210-3p levels in plasma predicted sur-
vival in critically ill patients with AKI. In this study, AKI patients presented higher levels of
miR-210-3p compared to healthy controls [31]. Additionally, a urine miRNA profile for AKI
has been recently published [32]. The data presented in these reports do not match with our
serum miRNA profile and levels, most probably due to the use of plasma and urine instead of
serum. miRNAs secreted to different body fluids and blood fractions could have different bio-
logical significance and functions.
Our data demonstrate that our panel of miRNAs shows a high diagnostic value with AUC
values between 0.9 and 1 in ROC analysis. This discriminative power is higher than that re-
ported for other AKI biomarkers currently in development, including NGAL, Cystatin C or IL-
18 [33].
Fig 3. SerummiRNAs are AKI precocious biomarkers in cardiac surgery patients.miR-26b-5p, miR-
146a-5p, miR-93-3p and miR-127-3p serum levels are expressed as ΔCp values and data is presented as
individual dots. AKI was diagnosed based on AKIN serum creatinine criteria. Spearman Rho correlation
coefficient was calculated and p-values are indicated in each panel.
doi:10.1371/journal.pone.0127175.g003
SerummicroRNAs as Acute Kidney Injury Biomarkers
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Fig 4. SerummiRNAs estimated before cardiac surgery identify patients in risk of AKI development. (A) miRNAs were detected by RT-qPCR in serum
samples obtained before surgery, expressed as ΔCp. Data are presented as median and interquartile range. Asterisks indicate statistical significance
(*P<0.05; ** P<0.01). (B) Spike-In raw Cp values are shown as control.
doi:10.1371/journal.pone.0127175.g004
SerummicroRNAs as Acute Kidney Injury Biomarkers
PLOS ONE | DOI:10.1371/journal.pone.0127175 June 16, 2015 11 / 15
An important characteristic of an AKI biomarker is the ability to achieve a precise quantifi-
cation of renal injury. Our results demonstrate that serum levels of miR-210-3p, miR-126-3p,
miR-29a-3p and miR-146a-5p show a significant correlation with AKIN stage classification, in-
dicating that these miRNAs could be used for deciphering AKI severity. Among the wide range
of new AKI biomarkers, only serum Cystatine-C levels correlate with AKI severity [34], al-
though others such as plasma NGAL can predict AKI progression in severity [35].
On the other hand, precocious AKI diagnosis is another valuable characteristic of the new
generation of AKI biomarkers. To assess this issue, we studied the expression of our panel of
miRNAs in a cohort of patients which underwent CS. This procedure can be considered a
quasi-experimental design since the moment of kidney insult is known and AKI development
and outcome can be closely monitored. Several biomarkers have been tested in this clinical
context to predict AKI immediately or few hours after intervention. They have demonstrated
very high predictive values in pediatric populations but more variable results in adults. NGAL
presented AUC values ranging from 0.54 to 0.87, IL-18 from 0.55 to 0.87, Cystatin-C from 0.73
to 0.76 and from 0.68 to 0.78 in the case of KIM-1 [36, 37].
In this regard, our correlation studies demonstrate that miR-26b-5p, miR-146a-5p, miR-93-
3p and miR-127-3p progressively decrease their expression levels in serum during the days
prior to AKI diagnosis by serum creatinine. These data demonstrate that serum miRNAs can
detect AKI development several days before serum creatinine. It is important to emphasize
that miR-146a-5p, which demonstrated a very high diagnostic value in ICU patients, presents
here a strong and significant downregulation during previous days to AKI. These data confirm
that this miRNA could be considered a precise and early AKI diagnostic tool in several clinical
contexts.
Fig 5. ROC analysis of serummiRNAs as AKI risk biomarkers. ROC curves of miR-26b-5p, miR-27a-3p, miR-93-3p and miR-127-3p expression levels in
serum, determined by qRT-PCR, in samples obtained before surgery.
doi:10.1371/journal.pone.0127175.g005
Table 6. ROC Curve analysis of serummiRNAs estimated in samples obtained before surgery.
RIFLE AKIN Creatinine Kinetics
AUC p-value AUC p-value AUC p-value
miR-26b-5p 0.821 0.006 0.722 0.024 0.908 0.000
miR-27a-3p 0.844 0.007 0.725 0.022 0.888 0.000
miR-93-3p 0.815 0.007 0.719 0.026 0.887 0.000
miR-127-3p 0.783 0.016 0.795 0.003 0.863 0.001
doi:10.1371/journal.pone.0127175.t006
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Remarkably, basal levels of miR-26b-5p, miR-27a-3p, miR-93-3p and miR-127-3p, mea-
sured before surgery, can robustly predict AKI development after CS, independently of the
AKI criteria used for diagnosis. They show a high predictive value with AUC values between
0.7 and 0.9. This evidence demonstrates that several miRNAs included in our panel can be con-
sidered as markers of AKI predisposition. Only KIM-1 has demonstrated this ability by pre-
dicting stage 3 AKI after CPB with an AUC value of 0.8 [38]. In fact, our data demonstrate for
the first time that serum miRNAs can predict AKI before surgery independently of its severity.
This valuable information could have a great impact in clinical practice, since it would allow
the detection of patients at risk of AKI development and would permit the application of pre-
vention strategies. None of the other biomarkers available so far can provide such benefit.
Conclusions
In this pilot study, we have identified and validated a panel of serum microRNAs as novel bio-
markers of AKI in ICU and CS patients. These serum miRNAs present a high diagnostic value
in ICU patients and their expression levels correlated with AKI severity.
Besides, in patients submitted to CS, serum miRNA levels could identify populations at risk
for AKI development after surgery. This ability has not been reported for any AKI biomarkers
up to this moment. Moreover, serum levels of these miRNAs progressively decreased days be-
fore AKI diagnosis, pointing out their potential role as early injury biomarkers.
Based on these results and consistently with other reports, serum miRNAs could be consid-
ered as a new generation of AKI diagnostic biomarkers, helpful for improvement of AKI pa-
tient management in clinical practice.
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